On August 23, Tasly Pharmaceutical Group (600535.SH) released its interim report for the first half of 2024. During the reporting period, the company achieved revenue of 4.372 billion yuan, a decrease of 0.46% year-on-year. The net income attributable to shareholders of the listed company was 0.662 billion yuan, a decrease of 6.33% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.735 billion yuan, an increase of 6.31% year-on-year. The basic earnings per share was 0.4433 yuan. It is planned to distribute a cash dividend of 2.6 yuan (tax included) per 10 shares to all shareholders.
The revenue decreased by 0.46% compared to the same period last year, with pharmaceutical industry revenue increasing by 4.55% and pharmaceutical commerce revenue decreasing by 28.08%. The net profit attributable to the parent company decreased by 6.33% compared to the same period last year, mainly due to the higher fair value loss of financial assets held by the company during the reporting period compared to the same period last year.